CN102727577A - Medicinal composition for treating gynecological inflammations - Google Patents
Medicinal composition for treating gynecological inflammations Download PDFInfo
- Publication number
- CN102727577A CN102727577A CN2011100896171A CN201110089617A CN102727577A CN 102727577 A CN102727577 A CN 102727577A CN 2011100896171 A CN2011100896171 A CN 2011100896171A CN 201110089617 A CN201110089617 A CN 201110089617A CN 102727577 A CN102727577 A CN 102727577A
- Authority
- CN
- China
- Prior art keywords
- medicinal composition
- pharmaceutical composition
- parts
- cell
- tests
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a medicinal composition for treating gynecological inflammations. The medicinal composition is characterized in that the medicinal composition comprises the following components, by weight, 5 parts of a chitosan oligosaccharide, 1 part of a Salvia miltiorrhiza extract, 0.65 parts of a Chinese angelica extract paste, and 0.75 parts of a Radix Astragali extract liquid. The medicinal composition of the invention is applied to wound restoration experiments, and results show that wounds are basically healed and there are no obvious scars. Cell proliferation tests prove that the medicinal composition is good for cell propagation and regeneration. The medicinal composition is applied to in vitro bacteriostatic tests, and results show that the medicinal composition has a stronger bacteriostatic capability than Anfushu, Ruchuangning and wound restoration agents. Acute toxicity tests of the medicinal composition are carried out in the invention, and the test medicinal composition is regarded as a nontoxic medicine through determining according to acute toxicity grading standards. So the medicinal composition of the invention can be used for treating the gynecological inflammations, and has large clinical application values.
Description
Technical field
The present invention relates to pharmaceutical composition, be specifically related to a kind of pharmaceutical composition of treating gynecological inflammation.
Background technology
At present, based on research, reported that it has antibiotic, antitumor, accent blood fat, regulates immunity and promotes multiple functions such as wound repair to oligochitosan.Because the oligochitosan pair cell has good affinity, oligochitosan itself is exactly the indispensable composition in the sugar chain structure of cell membrane top layer, plays iuntercellular identification in vivo, regulation and control, and information is passed on, effects such as contact inhibition.And the structure of oligochitosan and cell are closely similar; And can act directly on the cell through experiment proof oligochitosan, play the effect of good reparation damaged cell, and can recover the function of cell; Promote the growth of granulation tissue, and then promote the healing of wound.
But the inventor finds that when using oligochitosan that wound is treated separately, its effect is not very remarkable.The present invention is through being used with Radix Salviae Miltiorrhizae extract, eumenol, Huang Shi extracting solution and oligochitosan the present invention with certain proportion; Process new pharmaceutical composition; And pass through cell experiment; Zoopery and clinical experiment prove that it has the repair of strong effect to wound, and have good bacteria resistance function.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, and research design contains the pharmaceutical composition of oligochitosan, strengthens the wound repair effect.
The invention provides a kind of pharmaceutical composition that is used to treat gynecological inflammation.
Pharmaceutical composition of the present invention is grouped into by the one-tenth of following weight portion proportioning:
5 parts of oligochitosans, 1 part of Radix Salviae Miltiorrhizae extract, 0.65 part of eumenol, 0.75 part of Radix Astragali extractive solution.
Pharmaceutical composition of the present invention makes through following method:
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol then, Radix Astragali extractive solution 0.75g boils 5min, is cooled to room temperature then, crosses and filters out insoluble matter, promptly gets.
Pharmaceutical composition of the present invention is a spray, liniment.
Drug regimen raw material of the present invention obtains through commercially available.
The inventor has carried out extracorporeal bacteria inhibitor test to aforementioned pharmaceutical compositions, bacterial strain: staphylococcus aureus, escherichia coli, Candida albicans.The result is easypro with respect to the peace skin, decubital ulcer is peaceful, and the wound repair agent has stronger bacteriostasis.The inventor has carried out the acute toxicity test of aforementioned pharmaceutical compositions, judges according to acute toxicity grading criteria, originally receives the reagent thing to can be considered nontoxic.
Therefore, pharmaceutical composition of the present invention is used to treat gynecological inflammation.
The specific embodiment
Embodiment 1 preparation of pharmaceutical compositions
The drug regimen raw material obtains through commercially available.
Oligochitosan purity＞98% degree of polymerization＜10
The total ketone content of Radix Salviae Miltiorrhizae extract Radix Salviae Miltiorrhizae＞98%
Eumenol lactone content 1%, ferulic acid 0.8%
Radix Astragali extractive solution 0.75g/10ml
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol then, Radix Astragali extractive solution 0.75g boils 5min, is cooled to room temperature (25 ℃) then, crosses and filters out insoluble matter, promptly gets liniment.
The pharmaceutical composition that embodiment 1 makes is used for following test.
1. acute toxicity test
Experimental animal: 70 of kunming mices, body weight 17-22g, male and female half and half.Available from Shanghai Si Kelai laboratory animal Co., Ltd.
Animal divides into groups: adopt the male and female balanced at random method of dividision into groups respectively, being divided into is 7 groups, and 10 every group, wherein one group is the blank group.
Dosage is confirmed: metering is designed to 3ml/kg (clinical design dosage), 10ml/kg, 50ml/kg, 100ml.
| Group | Dosage ml/kg | Quantity | Survival rate % |
| 1 | 10 | 100 | |
| 2 | 3 | 10 | 100 |
| 3 | 10 | 10 | 100 |
| 4 | 50 | 10 | 100 |
| 5 | 100 | 10 | 100 |
Administration: disposable gastric infusion: before the administration fasting 3-5 hour, after the administration fasting 1-2 hour, water was can't help in fasting.Adopt administration in batches, negative control group, 3ml/kg, first administration of 5.0ml/kg confirms after the administration that set dosage is suitable, gives 10ml/kg and 10.0ml/kg again.Observe continuously after the administration more than 7 days, each observation of every day at upper and lower noon was subsequently once observed 14 days continuously.Itemized record each item observation index.
Conclusion: (solid drugs that is equivalent to 7.4g/kg) do not occur dead when being tried thing gastric infusion dosage reaching 100ml/kg in this test.Judge according to acute toxicity grading criteria, originally receive the reagent thing to can be considered nontoxic.
2. wound repair test
Experimental animal: the C57 mice, 16-18g, male, available from Shanghai Si Kelai laboratory animal Co., Ltd.
Test method: test mice is divided into blank control group, matched group 1 (U.S. 3M medical adhesive tape), matched group 2 (Britain executes expensive precious Convatee product), matched group 3 (golden English peptide EGF), experimental group, 20 every group.The modeling of mouse back QUMAO otch, wound surface is used iodophor disinfection, uses an amount of normal saline debridement then, then at surface coverage matched group 1 product, matched group 2 products; Spraying matched group 3 products and experimental group medicine, natural drying covers with sterile gauze at last.Wound recovery situation with regard to 3 days, 7 days and 14 days contrasts respectively.Result such as following table:
3. cell proliferation test
Cell strain: people's epidermis protein cell strain colo-16
Reagent: culture medium: DMEM contains 10% hyclone, 100 μ g/ml penicillins, the streptomycin of 100 μ g/ml; MTT uses the preceding solution that is made into 5mg/ml concentration with the PBS of PH 7.2; DMSO
Inoculation epidermis cell: when the colo-16 cell of cultivation is grown near monolayer; Draw and go up feelings liquid in the bottle, use 0.3% trypsinization, add an amount of DMEM and process the cell monolayer suspension; Be inoculated in 96 orifice plates, every hole 200 μ L put 37 degree, 5% CO2 gas incubator and cultivate.
Drug treating: inoculate after 24 hours, draw each hole supernatant and reach not attached cell, add matched group 1 (the peace skin relaxes) respectively, matched group 2 (golden English peptide EGF) after the experimental group dosing, continues to cultivate 3 days, and observation of cell is bred situation under inverted microscope.
The result: the propagation and the regeneration function of drug regimen pair cell are good.
| Group | Cell proliferation OD value |
| Matched group 1 | 0.18±0.034 |
| Matched group 2 | 0.15±0.032 |
| Experimental group | 0.35±0.048 |
4. extracorporeal bacteria inhibitor test
Bacterial strain: staphylococcus aureus, escherichia coli, Candida albicans.
Test method: the inoculation staphylococcus aureus, escherichia coli, Candida albicans is in the agar plate surface base.After getting aseptic filter paper and immerse in the medicine fully effect with aseptic nipper; Placing respectively, the agar plate of inoculated bacteria is put in the common incubator of 37 degree; Cultivated 18-24 hour under the aerobic situation, take out the observation bacterial growth situation and the scraps of paper and have or not antibacterial ring on every side, and measure the diameter that Israeli troops change.
Result of the test:
| Medicine | Staphylococcus aureus | Escherichia coli | Candida albicans |
| Matched group 1 | 6.49±0.55 | 8.01±0.19 | 6.54±0.72 |
| Matched group 2 | 6.25±0.37 | 7.59±0.65 | 6.37±0.28 |
| Experimental group | 8.13±0.25 | 10.39±0.57 | 9.0±0.34 |
Annotate: matched group 1: the peace skin relaxes, matched group 2 decubital ulcers are peaceful, experimental group: the wound repair agent
Conclusion: skin relaxes with respect to pacifying, decubital ulcer is peaceful, and the wound repair agent has stronger bacteriostasis.
Claims (3)
1. a pharmaceutical composition that is used to treat gynecological inflammation is characterized in that, said pharmaceutical composition
One-tenth by following weight portion proportioning is grouped into: 5 parts of oligochitosans, 1 part of Radix Salviae Miltiorrhizae, 0.65 part of Radix Angelicae Sinensis, 0.75 part of Radix Astragali extractive solution.
2. pharmaceutical composition according to claim 1 is characterized in that, said pharmaceutical composition makes through following method:
Get one in 200ml beaker, add 100ml and remove the thermal source distilled water, add 5g oligochitosan, 1g Radix Salviae Miltiorrhizae extract, 0.65g eumenol then, Radix Astragali extractive solution 0.75g boils 5min, is cooled to room temperature then, crosses and filters out insoluble matter, promptly gets.
3. pharmaceutical composition according to claim 1 is characterized in that, said pharmaceutical composition is spray or liniment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100896171A CN102727577A (en) | 2011-04-11 | 2011-04-11 | Medicinal composition for treating gynecological inflammations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011100896171A CN102727577A (en) | 2011-04-11 | 2011-04-11 | Medicinal composition for treating gynecological inflammations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102727577A true CN102727577A (en) | 2012-10-17 |
Family
ID=46984341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011100896171A Pending CN102727577A (en) | 2011-04-11 | 2011-04-11 | Medicinal composition for treating gynecological inflammations |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102727577A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107362294A (en) * | 2017-08-04 | 2017-11-21 | 四川梦思露生物科技有限公司 | One kind nursing antibacterial liquid and preparation method thereof |
| CN107773724A (en) * | 2016-08-30 | 2018-03-09 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat gynaecological imflammation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455347A (en) * | 2007-11-16 | 2009-06-17 | 刘洪生 | Angelica, astragalus, radix salviae nutrient effervescence tablet and manufacture method thereof |
-
2011
- 2011-04-11 CN CN2011100896171A patent/CN102727577A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455347A (en) * | 2007-11-16 | 2009-06-17 | 刘洪生 | Angelica, astragalus, radix salviae nutrient effervescence tablet and manufacture method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨声等: "水溶性壳聚糖和壳寡糖的吸湿、保湿性能及对几种致病菌的抑制作用研究", 《中国化妆品(行业)》 * |
| 高维等: "低分子量壳聚糖的制备及其应用研究", 《武汉工业学院学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107773724A (en) * | 2016-08-30 | 2018-03-09 | 苏州瑞美科生物技术有限公司 | A kind of pharmaceutical composition for being used to treat gynaecological imflammation |
| CN107362294A (en) * | 2017-08-04 | 2017-11-21 | 四川梦思露生物科技有限公司 | One kind nursing antibacterial liquid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104488986A (en) | Traditional Chinese medicine sterilizing liquid for clinical laboratory | |
| CN102836367B (en) | Bacteria-resisting, inflammation-diminishing and itching-relieving traditional Chinese medicine composition and preparation method and application thereof | |
| CN106265822A (en) | There are anti-inflammation raw myofunctional Mahonia bealei (Fort.) Carr. extract, preparation method and applications | |
| CN102727581B (en) | A kind of pharmaceutical composition wound to repair | |
| CN102727579B (en) | A kind of pharmaceutical composition being used for the treatment of oral ulcer | |
| CN102000197B (en) | Gargle for treating periapicalitis | |
| CN100502894C (en) | Method for preparing medicine of effective parts extracted from myrobalan for treating diseases infected by bacteria or virus | |
| CN102727577A (en) | Medicinal composition for treating gynecological inflammations | |
| CN102406858B (en) | Disinfection antibacterial agent | |
| CN111905058A (en) | Pharmaceutical composition for skin mucosa nursing and wound repair and preparation method thereof | |
| CN104840483A (en) | Medicine composition for treating skin wounds and medicinal preparation thereof | |
| CN103893300B (en) | A kind of Chinese medicine composition treating cow endometritis and preparation method and application | |
| CN103638052A (en) | Polyrhachis dives extractive, and preparation and medical purpose thereof | |
| CN102727578A (en) | Pharmaceutical composition for healing wounds generated by chemoradiotherapy | |
| CN105028501A (en) | Disinfectant for pharmacy | |
| CN102727580B (en) | A kind of pharmaceutical composition foot wounds to repair | |
| CN109248219A (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment brickpox | |
| CN103083448A (en) | Rhubarb and phellodendron medicinal pair extract for synergistically improving tinea pedis resistance | |
| CN103463202B (en) | Oral traditional Chinese medicine preparation for treating acne and production process of oral traditional Chinese medicine preparation for treating acne | |
| CN102078529B (en) | Chinese medicinal preparation for treating common cold in children | |
| CN101411839A (en) | Chinese medicine oral liquid for treating bacterial pneumonia and preparation method thereof | |
| CN101411749B (en) | Chinese medicinal composition for treating nasal sinusitis and allergic rhinitis | |
| CN107789393A (en) | A kind of pharmaceutical composition for treating wound caused by chemicotherapy | |
| CN105055504A (en) | Feed additive compound essential oil for preventing diarrhea of pigeons as well as preparation method and application of essential oil | |
| CN104840843A (en) | Female care solution and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20121017 |